Evidence map›Paper›PMID 35598178›Full record

ArticleEuropean journal of clinical investigation2022

Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence.

Arnaud G L'Huillier, Sabrina Pagano, Stephanie Baggio, Benjamin Meyer, Diego O Andrey, Mayssam Nehme, Idris Guessous, Christiane S Eberhardt, Angela Huttner, Klara M Posfay-Barbe and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Arnaud G L'HuillierDepartment of Woman, Pediatric Infectious Diseases Unit, Child and Adolescent Medicine, Geneva University Hospitals and Geneva University, Geneva, Switzerland.ORCID https://orcid.org/0000-0001-9230-7285
Sabrina PaganoDivision of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.ORCID https://orcid.org/0000-0001-7075-1182
Stephanie BaggioDivision of Prison Health, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Benjamin MeyerCentre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Diego O AndreyDivision of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.ORCID https://orcid.org/0000-0003-3247-9274
Mayssam NehmeDivision of Primary Care Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Idris GuessousDivision of Primary Care Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Christiane S EberhardtCentre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Angela HuttnerCentre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Klara M Posfay-BarbeDepartment of Woman, Pediatric Infectious Diseases Unit, Child and Adolescent Medicine, Geneva University Hospitals and Geneva University, Geneva, Switzerland.
Sabine YerlyDivision of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.
Claire-Anne SiegristCentre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Laurent KaiserDivision of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.
Nicolas VuilleumierDivision of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.
University Hospital of Geneva · CHUniversity of Geneva · CHUniversity of Bern · CH

Funding

De Reuter Foundation 657Fondation AncrageFondation de Bienfaisance du Groupe PictetFondation Prive des HUGGeneva University Hospitals and Faculty of Medicine's Center for VaccinologyGeneva University Hospitals and Faculty of Medicine's Centre for Emerging Viral Diseases.Geneva University Hospitals Project and Development GrantSchmidheiny Foundation
6 · The paper itself

Abstract

backgroundSARS-CoV-2 infection triggers different auto-antibodies, including anti-apolipoprotein A-1 IgGs (AAA1), which could be of concern as mediators of persistent symptoms. We determined the kinetics of AAA1 response over after COVID-19 and the impact of AAA1 on the inflammatory response and symptoms persistence.

methodsAll serologies were assessed at one, three, six and twelve months in 193 hospital employees with COVID-19. ROC curve analyses and logistic regression models (LRM) were used to determine the prognostic accuracy of AAA1 and their association with patient-reported COVID-19 symptoms persistence at 12 months. Interferon (IFN)-α and-γ production by AAA1-stimulated human monocyte-derived macrophages (HMDM) was assessed in vitro.

resultsAAA1 seropositivity was 93% at one month and declined to 15% at 12 months after COVID-19. Persistent symptoms at 12 months were observed in 45.1% of participants, with a predominance of neurological (28.5%), followed by general (15%) and respiratory symptoms (9.3%). Over time, strength of correlations between AAA1 and anti-SARS-COV2 serologies decreased, but remained significant. From the 3

conclusionCOVID-19 induces a marked though transient AAA1 response, independently predicting one-year persistence of respiratory symptoms. By increasing IFN-α response, AAA1 may contribute to persistent symptoms. If and how AAA1 levels assessment could be of use for COVID-19 risk stratification remains to be determined.

Indexed as

COVID-19Antibodies, ViralAntiviral AgentsApolipoprotein A-IAutoantibodiesHumansSARS-CoV-2Antibodies, ViralAntiviral AgentsApolipoprotein A-IAutoantibodiesanti-apolipoprotein A-1 autoantibodiesCOVID-19long COVID-19symptoms persistencetype I interferon response

Identifiers

PMID35598178
PMCPMC9348059
OpenAlexW4281263689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.